HK Stock Market Move | Hangzhou Tigermed Consulting (03347) opens more than 5% higher after the Yanxi High Company is expected to increase its attributable net profit for the year 2025 by 105% to 204% compared to the previous year.

date
09:29 30/01/2026
avatar
GMT Eight
Tiger Pharmaceuticals (03347) opened more than 5% higher after announcing a profit increase, rising 5.39% to HK$53.75 at the time of writing, with a trading volume of HK$1.6663 million.
Hangzhou Tigermed Consulting (03347) opened more than 5% higher, and at the time of the report, it had risen by 5.39% to HKD 53.75, with a turnover of HKD 1.6663 million. On the news front, on January 29, Hangzhou Tigermed Consulting issued an announcement stating that the group expects to achieve an operating income of RMB 6.66 billion to 7.68 billion in 2025, an increase of 1% to 16% year-on-year; net profit attributable to shareholders of the listed company is expected to be RMB 830 million to 1.23 billion, an increase of 105% to 204% year-on-year; and net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses is expected to be approximately RMB 330 million to 490 million, a decrease of 61% to 43% year-on-year. The announcement stated that the net profit attributable to shareholders of the listed company during the reporting period increased by 105% to 204% compared to the same period last year, mainly due to a significant increase in non-recurring gains and losses during the reporting period. During the reporting period, non-recurring gains and losses attributable to shareholders of the listed company amounted to RMB 500 million to 740 million; while in the same period of the previous year, non-recurring gains and losses attributable to shareholders of the listed company were approximately negative RMB 450 million, resulting in an increase of RMB 950 million to 1.19 billion in non-recurring gains and losses. Through unremitting efforts, the company saw significant growth in the number and amount of new signed orders compared to the same period last year. In 2025, the company's net new orders (new signed orders minus cancelled orders) are expected to be in the range of RMB 9.5 billion to RMB 10.5 billion, compared to RMB 8.420 billion in the same period in 2024.